Authorized purpose: Automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images, with optional comparison of volumetric data to reference percentile data; a support tool for structural-MRI assessment.
Clinical role
Automated post-processing segmentation, volumetry, morphometric reporting, and protocol-quality checking with trained-physician review.
Images and patients
MRI · Segmentable brain structures.
Key limitation
Keep in mind: Results must be reviewed by a trained physician. Automated quality controls include tissue-contrast checks and scan-protocol verification; the FDA packet establishes a support tool and segmentation/measurement evidence, not a diagnostic-outcome claim.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images, with optional comparison of volumetric data to reference percentile data; a support tool for structural-MRI assessment.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Segmentable brain structures. Input: MR brain images, including 3D T1 MRI series acquired under specified protocols; DICOM is supported as input.
Who uses it?Intended users: Clinicians and physicians skilled in brain MR imaging; results must be reviewed by a trained physician.
What does the software produce?Output: Segmented images with color overlays, volumetric measurements, morphometric reports, reference-percentile comparisons, a dedicated GUI for reviewing measures, a printable PDF report, and DICOM output displayable on DICOM workstations and PACS.
What is its most important limitation?Key limitation: Results must be reviewed by a trained physician. Automated quality controls include tissue-contrast checks and scan-protocol verification; the FDA packet establishes a support tool and segmentation/measurement evidence, not a diagnostic-outcome claim.
Clinical takeaway. Clinical role: Automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images, with optional comparison of volumetric data to reference percentile data; a support tool for structural-MRI assessment.
Evidence takeaway. Evidence from the reviewed source record: FDA performance testing used 300 T1-weighted scans from 10 scanner types for training, 64 T1 scans for accuracy, and 50 repeated T1 scans for reproducibility, with testing separate from training. Dice coefficients were 80-90% for major subcortical structures and 75-85% for major cortical regions; mean percentage absolute volume differences for major subcortical structures were 1-5%. These are segmentation-agreement and reproducibility endpoints, not sensitivity, specificity, or AUC.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images, with optional comparison of volumetric data to reference percentile data; a support tool for structural-MRI assessment.
Segmented images with color overlays, volumetric measurements, morphometric reports, reference-percentile comparisons, a dedicated GUI for reviewing measures, a printable PDF report, and DICOM output displayable on DICOM workstations and PACS.
Results must be reviewed by a trained physician. Automated quality controls include tissue-contrast checks and scan-protocol verification; the FDA packet establishes a support tool and segmentation/measurement evidence, not a diagnostic-outcome claim.
FDA performance testing used 300 T1-weighted scans from 10 scanner types for training, 64 T1 scans for accuracy, and 50 repeated T1 scans for reproducibility, with testing separate from training. Dice coefficients were 80-90% for major subcortical structures and 75-85% for major cortical regions; mean percentage absolute volume differences for major subcortical structures were 1-5%. These are segmentation-agreement and reproducibility endpoints, not sensitivity, specificity, or AUC.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA performance testing used 300 T1-weighted scans from 10 scanner types for training, 64 T1 scans for accuracy, and 50 repeated T1 scans for reproducibility, with testing separate from training. Dice coefficients were 80-90% for major subcortical structures and 75-85% for major cortical regions; mean percentage absolute volume differences for major subcortical structures were 1-5%. These are segmentation-agreement and reproducibility endpoints, not sensitivity, specificity, or AUC.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Neurophet AQUA regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K220437
Samplen=114
IndependenceIndependence not established
K220437
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K220437. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: MR brain images, including 3D T1 MRI series acquired under specified protocols; DICOM is supported as input.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Installed Windows software on off-the-shelf hardware with DICOM input/output, a dedicated GUI, and reports displayable on DICOM workstations and PACS; the FDA packet does not establish current cloud hosting.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Neurophet AQUA's deployment as installed, with a Windows operating system and operation on off-the-shelf hardware, while the predicate is listed as cloud based or installed. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Neurophet AQUA NeuroQuant Processing Segmentation based on deep Artifact correction, atlas-based" … "Operating Supports Linux, Mac OS X and Windows System Windows. Deployment Installed Cloud based or installed". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Segmented images with color overlays, volumetric measurements, morphometric reports, reference-percentile comparisons, a dedicated GUI for reviewing measures, a printable PDF report, and DICOM output displayable on DICOM workstations and PACS.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Segmented images with color overlays, volumetric measurements, morphometric reports, reference-percentile comparisons, a dedicated GUI for reviewing measures, a printable PDF report, and DICOM output displayable on DICOM workstations and PACS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Neurophet AQUA's deployment as installed, with a Windows operating system and operation on off-the-shelf hardware, while the predicate is listed as cloud based or installed. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Neurophet AQUA NeuroQuant Processing Segmentation based on deep Artifact correction, atlas-based" … "Operating Supports Linux, Mac OS X and Windows System Windows. Deployment Installed Cloud based or installed". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Installed Windows software on off-the-shelf hardware with DICOM input/output, a dedicated GUI, and reports displayable on DICOM workstations and PACS; the FDA packet does not establish current cloud hosting.
Neurophet announced on its press page and company history page that it obtained international information security certifications ISO 27001 and ISO 27701 (Korean-language pages).
Vendor-wide
Checked 2026-10-27
Vendor statement (Korean-language press release headline and history entry on the owning domain); the press page body did not render readable text on 2026-10-27 and certificates were not read. Exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Neurophet AQUA; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
6Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 6 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 6 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K220437 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Post-process previously acquired cervical-spine MR images to segment vertebrae and disks, calculate quantitative measurements, label out-of-range values, and export results for user review and interpretation.
Modality
MRI
Anatomy
Cervical spine: vertebrae C3-C7 and disks C2C3 through C7T1
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.